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Abstract 
Attenuation correction (AC) in PET/MRI is difficult as there is no clear relationship 
between MR signal and 511 keV attenuation coefficients (µ).  One strategy is to align a 
pre-defined atlas of µ to the PET/MRI for AC.  However, atlas design may influence 
quantitative accuracy of AC.  In this thesis we compare 3 atlas design strategies and 
evaluate their performance in an oncology patient population.  The 3 strategies were: 
correction with BMI-dependent atlases; gender-dependent atlases, and a gender- and sex-
independent atlas.  Patients were imaged with FDG PET/CT and 3T MRI.  The atlases 
were created and then used for PET AC of patients not included in the atlas construction.  
Resulting PET images were compared to CT-based PET reconstructions across all voxels 
and tissue-specific volumes.  For the purposes of AC, there is value in developing 
specialized atlases.  To this end, gender plays a more important role than body mass 
index in atlas construction. 
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Chapter 1  
1 Oncology Imaging in General 
Medical imaging is an integral component of comprehensive cancer care, whether 
looking at biological or pathological processes.  It provides us with many benefits, which 
include minimal to no invasiveness, real time monitoring, and can provide us with 
valuable information over wide ranges of time and size scales (1). 
 The importance of medical imaging is constantly growing in all aspects of cancer care 
(2, 3).  Some of the ways we are seeing medical imaging contribute include aiding with 
prediction (4), screening patients (5), preoperative staging (6), planning therapy (7), 
therapy guidance (8), and seeing how patients respond to therapy (9, 10).  Some of the 
modalities that have been instrumental in this progress include X-ray Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI), Single Photon Emission 
Computed Tomography (SPECT) and Positron Emission Tomography (PET); and more 
recently examples have emerged of multiple modalities being coupled together in so-
called “hybrid” modalities. 
1.1 X-ray Computed Tomography (CT) 
X-ray CT is among the most important of imaging technologies in cancer diagnosis and 
staging, and plays many roles.  For example, CT can be used for virtual colonography 
(11), providing information about colon tumors themselves as well as metastases in the 
lymph nodes and the liver (12, 13). X-ray CT is also frequently used to guide 
interventional procedures. Some of these include guided brachytherapy (14, 15), 
radiofrequency ablation of hepatic metastases and hepatocellular carcinoma (16), renal 
tumours (17), and of bone metastases (18), as well as transcatheter arterial 
chemoembolization (19), and guided biopsies (20-22). 
 In recent years, there is a growing trend of using X-ray CT for whole-body screening; 
however this application has received mixed opinions. For example, in a large study of 
1192 patients, 14% of scans were completely negative for any findings.  Of the remaining 
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86%, only 4% had a previous medical history reported.  The majority of findings were 
benign, and 37% were recommended for additional evaluation (23).  With so many of 
these findings being benign or requiring additional evaluation, one might question if there 
is a more efficient and lower risk modality for performing whole-body screening. 
 Conversely, some progress has been made to reduce dose in X-ray CT scanning. 
Recently, iterative reconstruction algorithms, originally developed for high-noise nuclear 
medicine tomographic applications, have been ported to CT. These methods allow 
radiation dose in CT scanning to be reduced without sacrificing image quality.  Various 
iterative reconstruction techniques have seen dose reductions from 25-65% (24-26). 
 X-ray CT has also seen a growing convergence with radiotherapy treatment 
planning (27-29), which has promoted the use of larger x-ray detectors and higher power 
x-ray tubes. These developments, along with temporal gating of scanning (“4D” 
scanning) has improved the usefulness of CT for tumour tracking at every point 
throughout the breathing cycle.  Combining this with Intensity Modulated Radiotherapy, 
an advanced type of high-precision radiation therapy that also relies upon temporal 
gating, improves the ability to deliver efficacious therapeutic radiation doses to the tumor 
site while sparing surrounding tissue (30). 
1.2 Magnetic Resonance Imaging (MRI) 
MRI is among the most flexible of imaging modalities in terms of its ability to derive a 
multitude of contrasts from both endogenous tissue properties, as well as detect the 
presence of exogenous contrast agents introduced into the body.   
 The majority of clinical MRI relies on signal derived from the hydrogen nuclei.  The 
hydrogen nuclei consist of a single proton and, therefore, have a net magnetic moment 
and spin of 1/2.  Hydrogen nuclei are most abundant in tissue, water and lipids and act 
like microscopic bar magnets rotating along their longitudinal axis.  Typically, the 
magnetic moments of hydrogen protons within a sample are oriented in random 
directions, resulting in no net magnetization of the sample at the macroscopic level.  
However, when the sample is placed within a strong static magnetic field, the protons 
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will start to precess about the orientation of the static field.  The proton will then be in a 
mixed energy state composed of two eigenstates referring to the direction of the 
longitudinal component of the proton’s magnetic moment: the parallel state and the 
antiparallel state. Over a brief period of time, energy exchange with the surrounding 
lattice through thermodynamic processes (rotations and vibrations) will result in a slight 
excess of protons in the parallel state (i.e. lower energy state). This will result in the 
acquisition of a net macroscopic magnetization by the sample in the direction of the 
MR’s static field.  This net magnetization is where we derive our signal to produce our 
image.  The frequency of the proton’s precession is determined from the Larmor 
equation: 
ω = γ B0 
where γ  is the gyromagnetic ratio, which is equal to 42.6 MHz/T and B0 is the main 
magnetic field strength of the MR scanner.  In order to exploit resonant absorption of the 
MR transmitted RF electromagnetic field, the frequency must be selected to match at the 
precessional frequency of the protons, which is calculated via the Larmor equation.  The 
RF field produces a new effective direction of the magnetic field experienced by the 
protons and they will start to precess around this direction, resulting in the net 
magnetization rotating away from the longitudinal direction of the main field.  The 
amount of rotation, or the flip angle, depends on the strength and duration of the RF 
pulse.  A flip angle of 90o will maximize the amount of transverse magnetization 
produced. This is important as only the transverse component of the magnetization will 
induce a detectable signal in the MRI receiver coil.  The same inter-molecular 
interactions that allowed the formation of the macroscopic magnetization, T1 processes, 
will force the return of the magnetization to its equilibrium state along the direction of the 
main field.  The rate at which the magnetization returns to the longitudinal axis is 
different for protons in different tissues.  It is this tissue-specific variation in the rate of 
its magnetization’s return to equilibrium which provides the fundamental source of 
contrast in T1-weighted images.   
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 T2 is a parameter that characterizes the rate of dephasing, or loss of coherence, of the 
protons associated with a given tissue.  Transverse relaxation begins with the net 
magnetization aligned perpendicular to the direction of the main field.  As spins 
experience random field fluctuations due to the field produced by the movement of 
neighboring spins, the phase of the individual spins forming the macroscopic 
magnetization progressively loses coherence and the resulting magnitude of the vector 
sum diminishes exponentially with time.  Different tissues have different T2 values due 
to their different molecular composition and therefore, T2 decay is another source of 
contrast in MRI.   
 Echo Time (TE) is the time between the peak of the excitation RF pulse and the peak 
of the echo that is formed from rephasing of the spins.  Repetition Time (TR) is the time 
that it takes to run through the pulse sequence once.  The pulse sequence typically needs 
to be repeated 256 times to construct an image with 256 lines.  TE and TR can be used to 
control the amount of “weighting” of these T1 and T2 effects in our image.  A change in 
TR will control the amount of T1-weighting and a change in TE will control the amount 
of T2-weighting.   
 Many MRI-based methods can be applied to cancer detection and staging, evaluation 
of therapeutic response and even biopsy guidance. Herein, our literature survey will list 
only a few examples meant to illustrate the flexibility of MRI. 
 An application of MRI that is growing rapidly in profile is breast imaging. Breast MR 
imaging is very important for staging because of its ability to show multi-focal tumours, 
involvement of other anatomy, and presence of metastases. MRI has been shown to be 
superior to ultrasound and mammography for assessing pathological response to 
treatment and a low rate of re-operation (9.5%) for positive margins after breast 
conserving surgery (31).  This makes MRI an important tool in aiding clinical decision-
making between breast-conserving surgery versus mastectomy. 
 Another area receiving increased attention for oncological applications is MRI 
Diffusion Weighted Imaging (DWI), a method in which the MRI contrast is dependent on 
the ability of water molecules to diffuse freely within the tissue. This has utility in cancer 
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imaging because tumour tissue tends to feature microstructural abnormalities that affect 
the diffusion of water molecules and lower the apparent diffusion coefficient (ADC).  
This allows the tumors to be detected as bright signals on diffusion-weighted images and 
signal voids on ADC maps.  DWI is also useful in monitoring therapeutic response since 
observed increases in ADC following therapy are thought to result from cellular water 
being freed into the extracellular space following cancer cell death (32).  Therefore, a 
positive response to therapy is indicated by a rise in ADC.  An example of this can be 
seen with changes in hepatic metastases from neuroendocrine tumours following 
transarterial chemoembolization imaged with DWI MRI of the liver (33). 
 As with many medical imaging modalities, MRI images can rely upon either 
endogenous contrast or exogenous contrast agents introduced into the body. There are 
many examples of the latter; however, one exogenous contrast agent that has been 
attracting considerable attention recently is Ultra Small Particle Iron Oxide (USPIO). 
Accumulation of this contrast agent causes a sharp reduction (loss) in an MR imaging 
parameter known as T2*.  An example of USPIO application is in the detection of lymph 
node involvement in the spread of cancer from a primary tumor site.  In many cases, 
diseased lymph nodes become enlarged, relative to their healthy counterparts – making 
the diseased nodes easy to detect.  However, diseased nodes, which are not enlarged 
become difficult to detect. In a recent study, combining USPIO MRI and a different 
imaging modality - Positron Emission Tomography using the 18F-based radiotracer 
fluorodeoxyglucose - achieved 100% sensitivity, specificity, positive predictive value, 
and negative predictive value in diseased lymph node detection in breast imaging, as 
confirmed by histopathology (34). Further to this success, USPIO MRI is also receiving 
attention in evaluating lymph node involvement with prostate, colorectal cancer and lung 
cancer. 
1.3 Nuclear Medicine Imaging 
Nuclear medicine modalities consist of Single Photon Emission Computed Tomography 
(SPECT) and Positron Emission Tomography (PET). Unlike X-ray Computed 
Tomography and Magnetic Resonance Imaging, the nuclear medicine modalities do not 
image endogenous contrast. However, their ability to detect their associated gamma-ray 
6 
 
emitting exogenous contrast agents remains far unchallenged. SPECT, and moreso PET, 
are capable of detecting contrast agents in the nanomole/kg and picomole/kg 
concentrations. In comparison, X-ray CT has sensitivities of a few millimole/kg, while 
MRI sensitivity has been reported to be approximately 10 millimole/kg (1). The high 
sensitivity of nuclear medicine modalities allows the use of relatively little exogenous 
contrast and the benefit of having an exceedingly low rate of pharmacological reaction 
(1). 
 In both SPECT and PET, the exogenous contrast agent is referred to as a radiotracer. 
It is comprised of a radioactive atom that emits gamma-rays upon its radioactive decay; 
and a molecule that has biological relevance. The biological relevance can include 
affinity to certain types of cells, or properties that facilitate or prevent diffusion across a 
membrane. In general, these radiotracer properties allow detection of cell populations, 
measurement of filtration or blood flow, and, by extension, the differentiation of diseased 
tissues from healthy tissues.  In many cases, abnormal tracer uptake can be indicative of 
disease processes such as cancer (35) or tissue damage, as would be the case following a 
heart attack (36). SPECT and PET are often referred to as functional imaging modalities, 
since they show tissue health, rather than anatomical structure. SPECT and PET differ in 
that the latter relies upon the detection of pairs of gamma-rays, in contrast to Single 
Photon Emission Computed Tomography. 
 Both SPECT and PET have a multitude of uses in oncology. For SPECT, we will 
survey two examples that have received increased attention in recent reports. We will 
then turn our attention to PET, where exciting applications are growing at an exponential 
rate. 
1.3.1 SPECT 
A long-standing, but growing, application of oncologic SPECT is in the identification of 
the Sentinel Lymph Node (SLN), which is the first lymph node met by lymphatic vessels 
draining a tumour (37).  The absence of tumour cells in the SLN could indicate the 
absence of metastatic disease in other surrounding nodes.  If the SLN is identified and 
found to contain no tumour cells, extensive node dissection surgery can be avoided. 
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Lymph node drainage patterns can be seen by SPECT using 99mTc-labelled human serum 
albumin (38, 39). In a review of 14 articles on the role of SPECT/CT – a form of SPECT 
that is combined with X-ray CT –  in the preoperative detection of sentinel lymph nodes 
in breast cancer (40), the authors found that SPECT/CT improved both identification and 
staging of breast cancer when compared with planar lymphoscintigrams. 
 SPECT has, and continues to, see roles in pharmaceutical development, where 
radiotracer versions of therapeutic drugs are used to measure pharmacokinetics and 
identify the ultimate fate of the drug. Here, SPECT has accelerated drug development and 
minimized the effort spent on ineffective treatments for cancer patients (41). An example 
of this can be seen with the use of folate-targeted imaging agents to predict response to 
therapy with folate-targeted therapy in advanced ovarian cancer (42).  In this study it was 
suggested that use of folate receptor targeted EC20 (a 99mTc-labeled imaging agent) 
imaging can identify patients with advanced ovarian cancer who are most likely to 
benefit from therapy with folate receptor targeted EC145. 
1.3.2 PET in Oncology 
PET, like SPECT, seeks to measure the distribution of an administered radiotracer. In the 
case of radiotracers designed for PET, however, the radioactive atoms on the tracers do 
not themselves emit gamma-rays. Instead, they decay (often but not always) by emitting a 
positron – the anti-matter counterpart to the electron. This positron travels a certain 
distance, determined by its kinetic energy, and then interacts with an electron in mutual 
annihilation, leading to the emission of two 511 keV gamma-rays in nearly opposite 
directions. The PET scanner detects these two gamma-rays in near time-coincidence. By 
repeatedly detecting these events, the PET scanner is able to measure projections of the 
distribution of the administered radiotracer. Then, using the principles of computed 
tomography, similar to those found in SPECT and X-ray CT, these projections are 
combined to create a three-dimensional representation of the radiotracer distribution in 
the body. 
 PET has seen broad applications in oncology, cardiology and neurology. It features a 
number of advantages over its single photon counterpart: more flexible radiochemistry 
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which allows a greater selection of radiotracers to be developed, shorter half-lives of 
radionuclides simplifying repeat studies in individuals, and increased sensitivity to low 
concentrations of radiotracers. However, PET has always been more expensive than 
SPECT, which contributed to its smaller deployment historically. 
 However, in the 1990s, an important invention was made that would change PET – 
and many imaging modalities – forever: the hybridization of imaging modalities. A PET 
scanner was combined with an X-ray CT scanner, leading to PET/CT (Patent No: US 
6,490,476 B1; Townsend, D.W et al, Nuclear Science Symposium, 1998. Conference 
Record. 1998 IEEE).  Now, for the first time, the exquisite biological information made 
available via visualizing radiotracer distribution was combined with the anatomical 
referencing made possible with X-ray CT. This is in part why PET/CT has become such a 
powerful tool for the detection of cancer. For example, in conjunction with the 
radiotracer 18F-FDG, the sensitivity of PET/CT aids in the early detection of tumours, 
allowing for early treatment (43) and its high specificity aids in the identification of non-
specific benign lesions (44, 45).  In tumor staging: FDG-PET has been found to be more 
accurate than CT in staging disease in the mediastinum in patients with lung cancer (46).  
Further still, integrated FDG-PET/CT has been found to be even better at predicting stage 
I and II disease as well as size of the tumor and whether it has invaded nearby tissue (T) 
and regional lymph nodes that are involved (N), of patients with non-small cell lung 
cancer (NSCLC) when compared with dedicated PET alone.  There were similar findings 
in a study of 27 patients with lymphoma, which concluded that FDG-PET/CT imaging 
was accurate in re-staging lymphoma and offered advantages over separate FDG-PET 
and CT imaging (47). In the same way that SPECT can be used to assess cancer response 
to a therapeutic prescription to determine efficacy early on during treatment, PET can be 
used for follow-up scans to detect progressive disease or recurrence.  Van Loon et al 
(2009) found that PET-scanning after curative treatment for NSCLC led to the detection 
of progression, and that selectively offering a PET/CT scan to the patients without 
symptoms could possibly lead to an effective follow-up method (48). 
 Also, like SPECT radiotracers, drugs can be labelled with a radionuclide without 
changing the drug’s biochemical properties.  This makes it possible to use trace quantities 
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of a drug to predict its pharmacokinetics and distribution at therapeutic quantities with 
less probability for unintended reactions. Various radiolabeled chemotherapy agents have 
been studied, such as [18F]tamoxifen (49), [18F]fluorouracil (50), and [18F]paclitaxel (51). 
1.3.3 18F-fluorodeoxyglucose (FDG) 
Of the many potential radioisotope tracers that could be used in PET imaging, FDG is 
one that has proven most useful particularly in oncology imaging. FDG is a molecule that 
is very similar to glucose, and shares many – but not all – of its biochemical traits. 
 FDG is labeled with the radionuclide 18F. A popular method for producing 18F is in a 
medical cyclotron. A cyclotron is a particle accelerator used to accelerate charged 
particles outwards from the center along a spiral path (Figure 1-1).  
 
A static magnetic field holds the particles to the spiral path and they are accelerated by a 
rapidly varying electric field. In the case of 18F, the cyclotron is used to bombard 18O 
Electromagnet (South Pole) 
Electromagnet (North Pole) 
 
Acceleration Hollow Electrode  
Chambers (Dees) 
Particle’s Spiral 
Path Charged Particle 
Target 
Alternating Current 
Source 
Figure 1-1: Cyclotron - Positive ions created inside are accelerated between the hollow 
electrode chambers (Dees) by a square wave electric field, which reverses just as the ions 
approach the gap.  The ion path spirals away from the center, perpendicular to the field 
direction until they collide with the target. 
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atoms (chemically present as 18O enriched water) with high energy protons, resulting in 
the reaction: 
 
 
 The FDG molecule itself differs from glucose in that the 18F substitutes for a hydroxyl 
group in the 2’ position, as shown in Figure 1-2. 
 
Figure 1-2:  2-Deoxy-2-(18F) Fluoro-D-Glucose 
 In the body, glucose is central to the production of metabolic energy. Typically, 
after glucose is consumed by an individual, it becomes distributed in the blood, and is 
taken up by cells via membrane-bound glucose transport proteins (See Figure 1-3). Inside 
the body’s cells, glucose interacts with an enzyme known as hexokinase, and becomes 
phosphorylated, forming glucose-6-phosphate. This new molecule then reacts with 
glucose-6-isomerase to form fructose-6-phosphate, and finally enters the Krebs cycle. 
 FDG, like glucose, enters the cell via membrane transport proteins; and then 
undergoes phosphorylation by hexokinase. However, the resulting FDG-6-phosphate 
cannot interact with glucose-6-isomerase, and hence does not proceed to the Krebs cycle. 
Instead, FDG-6-phosphate merely accumulates in the cell – where it ultimately serves as 
an indicator of glycolytic activity. This feature of FDG makes it extremely useful in 
oncology since glycolysis is greater in many tumour cells than in their healthy 
counterparts (52). In general, the increased FDG observed in cancerous tissue is due to 
upregulated activities of glucose transporters (GLUT1 and GLUT3) and hexokinases (I 
and II) (53, 54).  Although glycolytic rate can be regulated at many different steps in the 
